NOSOPHARM
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.
NOSOPHARM
Industry:
Biotechnology Pharmaceutical Product Research
Founded:
2009-01-01
Address:
Nîmes, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.nosopharm.com
Total Employee:
1+
Status:
Active
Contact:
+330466265321
Email Addresses:
[email protected]
Total Funding:
4.27 M EUR
Technology used in webpage:
COVID-19 Gravatar Profiles 3 To 9 CcTLD Redirects
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Photoderma
PhotoDerma SA is a development stage company engaged in research and development of novel cosmetics and pharmaceutics.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Debt Financing - Nosopharm
Auriga Partners
Auriga Partners investment in Venture Round - Nosopharm
KREAXI
KREAXI investment in Venture Round - Nosopharm
Alto Invest
Alto Invest investment in Venture Round - Nosopharm
Auriga Partners
Auriga Partners investment in Venture Round - Nosopharm
Alto Invest
Alto Invest investment in Venture Round - Nosopharm
KREAXI
KREAXI investment in Venture Round - Nosopharm
More informations about "Nosopharm"
Nosopharm | First-in-class Anti-Infectives
Nosopharm is an innovative biotechnology company specialized in anti-infective drug discovery . Our mission is to discover and develop new anti-infective drugs to combat antimicrobial …See details»
About Nosopharm
At Nosopharm our mission is to discover and develop first-in-class therapies to treat infectious diseases, especially in the context of antimicrobial resistance. Infectious diseases are a major cause of global mortality, leading to more than …See details»
Science - Nosopharm
Nosopharm has been developing and improving its proprietary, unique drug discovery platform for more than a decade. This platform exploits the bacteria Photorhabdus and Xenorhabdus to …See details»
Nosopharm - LinkedIn
Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The...See details»
Nosopharm - Crunchbase Company Profile & Funding
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance …See details»
nosopharm - AMR Industry Alliance
The AMR Industry Alliance brings together biotech, diagnostics, generics and research-based pharmaceutical companies, to drive and measure industry progress to curb antimicrobial …See details»
Nosopharm - selectscience.net
Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial …See details»
Advancing first-in-class anti-infective therapies to combat …
Nosopharm is an innovative biotechnology company that is focused on exploring untapped microbial biodiversity to discover new drugs to fight antimicrobial resistance. Infectious …See details»
Nosopharm - VentureRadar
Website: http://www.nosopharm.com/ Develops innovative anti-infectious drugs by leveraging biotechnology, focusing on novel therapeutic solutions to combat antibiotic resistance in a …See details»
Nosopharm Company Profile 2024: Valuation, Funding & Investors …
Nosopharm is headquartered in Lyon, France. What is the size of Nosopharm? Nosopharm has 7 total employees. What industry is Nosopharm in? Nosopharm’s primary industry is Drug …See details»
Pipeline - Nosopharm
Nosopharm’s anti-infective pipeline focuses on the treatment of infectious diseases, particularly in the context of antimicrobial resistance. Our lead R&D programs are based on our unique expertise in the exploitation of the bacteria …See details»
Nosopharm Company Profile - Office Locations, Competitors, …
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance …See details»
GNA NOW - IMI AMR Accelerator
Under the global umbrella of IMI’s AMR Accelerator, the Gram-Negative Antibacterials NOW Consortium (GNA NOW) is a six-and-a-half year project aimed at bringing together key …See details»
Advancing first-in-class anti-infective ... - Nature
Nosopharm is an innovative biotechnology company that is focused on exploring untapped microbial biodiversity to discover new drugs to fight antimicrobial resistance.See details»
Nosopharm raises funds to accelerate development of NOSO …
Mar 29, 2017 · French biotechnology company Nosopharm has raised €2.4m in funding with Auriga Partners, Kreaxi and Alto Invest to accelerate the regulatory preclinical development of …See details»
Nosopharm welcomes new members to supervisory board
Lyon, France, July 11, 2022 – Nosopharm, specialized in exploring unconventional sources of antibiotics, to discover new drugs to fight antimicrobial resistance, today announces several …See details»
☑️Nosopharm — Consulting Organization from France, …
Nosopharm — Consulting Organization from France, has experience with The Seventh Framework Programme, Horizon 2020 (2014 - 2020), it`s involved in Health, Science & …See details»
Nosopharm brings antibiotic one step closer to clinical development
Jun 9, 2022 · Discovered by Nosopharm from a Xenorhabdus bacteria, NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant …See details»
News - Nosopharm
Nosopharm is open to synergistic collaborations for the development of its pipeline and the progress of its promising drug discovery programs. Our goal is to explore, with an industrial …See details»
NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS …
Jun 8, 2022 · NOSO-502 is being developed by Nosopharm in partnership with GNA NOW, a European Consortium funded by the Innovative Medicines Initiative 2 (IMI2). NOSO-502 is the …See details»